Kovitz Investment Group Partners, LLC Vertex Pharmaceuticals Inc Transaction History

Kovitz Investment Group Partners, LLC

$15 Billion
Q3 2024

A detailed history of Kovitz Investment Group Partners, LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Kovitz Investment Group Partners, LLC holds 36,083 shares of VRTX stock, worth $16.4 Million. This represents 0.11% of its overall portfolio holdings.

Number of Shares

36,083

Previous 31,445 14.75%

Holding current value

$16.4 Million

Previous $14.7 Million 13.86%

% of portfolio

0.11%

Previous 0.14%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$460.0 - $505.78 $2.13 Million - $2.35 Million	4,638 Added 14.75%	36,083 $16.8 Million
Q2 2024 Aug 14, 2024	BUY	$392.81 - $485.53 $11.7 Million - $14.5 Million	29,843 Added 1862.86%	31,445 $14.7 Million
Q1 2024 May 14, 2024	BUY	$407.69 - $446.08 $653,119 - $714,620	1,602 New	1,602 $669,000
Q1 2022 Apr 22, 2022	SELL	$221.42 - $260.97 $692,601 - $816,314	-3,128 Closed	0 $0
Q4 2021 Feb 04, 2022	SELL	$177.01 - $223.45 $1.08 Million - $1.37 Million	-6,110 Reduced 66.14%	3,128 $739,000
Q3 2021 Oct 28, 2021	SELL	$181.39 - $202.99 $438,963 - $491,235	-2,420 Reduced 20.76%	9,238 $1.68 Million
Q2 2021 Aug 04, 2021	BUY	$187.49 - $221.1 $1.13 Million - $1.34 Million	6,040 Added 107.51%	11,658 $2.35 Million
Q1 2021 May 06, 2021	BUY	$207.02 - $241.31 $515,479 - $600,861	2,490 Added 79.6%	5,618 $1.21 Million
Q4 2020 Feb 12, 2021	SELL	$207.01 - $276.09 $333,286 - $444,504	-1,610 Reduced 33.98%	3,128 $739,000
Q3 2020 Nov 10, 2020	BUY	$255.65 - $303.1 $1.21 Million - $1.44 Million	4,738 New	4,738 $1.29 Million

Others Institutions Holding VRTX

# of Institutions

1,728

Shares Held

223M

Call Options Held

1.65M

Put Options Held

1.38M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $116B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Kovitz Investment Group Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Kovitz Investment Group Partners, LLC with notifications on news.

Account

Kovitz Investment Group Partners, LLC Vertex Pharmaceuticals Inc Transaction History